Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rayaldee in Secondary Hyperparathyroidism with Stage 3/4 CKD
NCT01704079Phase 3Completed
- Sponsor
- OPKO Health
- Start
- Nov 2012
- Primary completion
- Aug 2014
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in secondary hyperparathyroidism (SHPT) comparing Rayaldee with Placebo (2 arms). Primary endpoint: Proportion of Participants with Decrease in Plasma Intact Parathyroid Hormone (iPTH) of >=30% From Pre-treatment Baseline at 26 weeks. Started Nov 2012; status: completed.
02
Drugs
calcifediol
03
Conditions
secondary hyperparathyroidism (SHPT)
Beyond the preview
Go deeper on NCT01704079.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01704079.